Добірка наукової літератури з теми "Cancer immunotherapies"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Cancer immunotherapies".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Cancer immunotherapies"
Bergman, Philip J. "Cancer Immunotherapies." Veterinary Clinics of North America: Small Animal Practice 49, no. 5 (September 2019): 881–902. http://dx.doi.org/10.1016/j.cvsm.2019.04.010.
Повний текст джерелаDAVIS, Ian D., and Jonathan S. CEBON. "Developing cancer immunotherapies." Asia-Pacific Journal of Clinical Oncology 7 (March 24, 2011): 9–13. http://dx.doi.org/10.1111/j.1743-7563.2011.01382.x.
Повний текст джерелаOtt, Patrick A. "Intralesional Cancer Immunotherapies." Hematology/Oncology Clinics of North America 33, no. 2 (April 2019): 249–60. http://dx.doi.org/10.1016/j.hoc.2018.12.009.
Повний текст джерела&NA;. "Immunotherapies for cancer reviewed." Inpharma Weekly &NA;, no. 1432-1433 (April 2004): 2. http://dx.doi.org/10.2165/00128413-200414320-00001.
Повний текст джерелаGubens, Matthew A. "Immunotherapies for Lung Cancer." Journal of the National Comprehensive Cancer Network 15, no. 5S (May 2017): 692–95. http://dx.doi.org/10.6004/jnccn.2017.0075.
Повний текст джерелаFakhrejahani, Farhad, Yusuke Tomita, Agnes Maj-Hes, Jane B. Trepel, Maria De Santis, and Andrea B. Apolo. "Immunotherapies for bladder cancer." Current Opinion in Urology 25, no. 6 (November 2015): 586–96. http://dx.doi.org/10.1097/mou.0000000000000213.
Повний текст джерелаBerraondo, Pedro, Sara Labiano, Luna Minute, Iñaki Etxeberria, Marcos Vasquez, Alvaro Sanchez-Arraez, Alvaro Teijeira, and Ignacio Melero. "Cellular immunotherapies for cancer." OncoImmunology 6, no. 5 (May 2, 2017): e1306619. http://dx.doi.org/10.1080/2162402x.2017.1306619.
Повний текст джерелаMulé, James J., and Jeffrey S. Weber. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1153. http://dx.doi.org/10.1038/nm1104-1153a.
Повний текст джерелаPardoll, Drew, and James Allison. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1153–54. http://dx.doi.org/10.1038/nm1104-1153b.
Повний текст джерелаSkipper, Jonathan, Eric W. Hoffman, Jill O'Donnell-Tormey, and Lloyd J. Old. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1154–55. http://dx.doi.org/10.1038/nm1104-1154.
Повний текст джерелаДисертації з теми "Cancer immunotherapies"
Murray, Abner A. "Plant Virus Nanoparticle In Situ Cancer Immunotherapies." Case Western Reserve University School of Graduate Studies / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=case1532370850718292.
Повний текст джерелаMoynihan, Kelly D. (Kelly Dare). "Engineering immunity : enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer." Thesis, Massachusetts Institute of Technology, 2017. http://hdl.handle.net/1721.1/113960.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references (pages 127-140).
Checkpoint blockade with antibodies against CTLA-4 or PD-1 has demonstrated that an endogenous adaptive immune response can be stimulated to elicit durable tumor regressions in metastatic cancer, but these dramatic responses are confined to a minority of patients¹-³. This outcome is likely due in part to the complex network of immunosuppressive pathways present in advanced tumors, which necessitates the development of novel therapeutics and combination immunotherapies to generate a counter-directed network of pro-immunity signals⁴-⁸. In Chapters 2 and 3 of this thesis, we describe methods for enhancing T cell priming against tumor antigens via covalent modification of molecular vaccines to enhance lymphatic drainage, serum stability, or cytosolic access to improve presentation on MHC class I. In Chapter 4, we demonstrate a combination immunotherapy that recruits a diverse set of innate and adaptive effector cells, enabling robust elimination of large tumor burdens that to my knowledge have not previously been curable by treatments relying on endogenous immunity. Maximal anti-tumor efficacy required four components: a tumor antigen targeting antibody, an extended half-life IL-2⁹, anti-ƯPD-1, and a powerful T-cell vaccine¹⁰. This combination elicited durable cures in a majority of animals, formed immunological memory in multiple transplanted tumor models, and induced sustained tumor regression in an autochthonous BRraf[superscript V600E]/Pten[superscript -/-] melanoma model. Finally, in Chapter 5, we show preliminary data on combination immunotherapies used to treat antigenically heterogeneous tumors. Taken together, these data define design criteria for enhancing the immunogenicity of molecular vaccines and elucidate essential characteristics of combination immunotherapies capable of curing a majority of tumors in experimental settings typically viewed as intractable.
"During my doctorate by the John and Fanny Hertz Foundation Fellowship (specifically the Wilson Talley Hertz Fellowship), the NSF Graduate Research Fellowship Program, and the Siebel Scholarship"--Page 141. "This thesis work was supported in part by the Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute, the US National Institutes of Health (NIH) grant CA174795, the Bridge Project partnership between the Koch Institute for Integrative Cancer Research and the Dana Farber-Harvard Cancer Center (DF-HCC), the V Foundation, the Ragon Institute, and the Howard Hughes Medical Institute"--Page 141.
by Kelly D. Moynihan.
Ph. D.
Natarajan, Gayathri. "THE USE OF A TEC KINASE INHIBITOR, IBRUTINIB, FOR THE DEVELOPMENT OF IMMUNOTHERAPIES AGAINST CANCER AND LEISHMANIASIS." The Ohio State University, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=osu1461200133.
Повний текст джерелаMustapha, Rami. "Evaluation of novel anti-tumoral strategies using peptide or monoclonal antibody immunotherapies." Thesis, Lille 1, 2016. http://www.theses.fr/2016LIL10198/document.
Повний текст джерелаThe immune system can recognize and eliminate cancer cells but is held back by inhibitory factors such as Regulatory T cells (Tregs). Gal-9 is a β-galactoside binding lectin with immunosuppressive capabilities expressed by cancer cells and immune cells including Tregs. NPC is a malignant epithelial cancer which is almost always associated with Epstein Bar Virus (EBV) and expresses several viral proteins. Numerous vaccines targeting different EBV peptides had limited success in clinical trials. First part: we aimed to confirm the role of Gal-9 in human Treg function. Then we tested the capabilities of an anti-human-Gal-9 antibody (mAb) to block Gal-9 suppressive function and its effect on Treg function and the anti-tumoral response. We proved that Gal-9 is expressed and secreted by Tregs at a high level. The mAb antagonized the function of recombinant rGal-9 on PBMCs. Moreover, the mAb inhibited the immuno-suppressive function of Tregs. Gal-9 blocking in PBMC culture promoted a Th1 response without inducing toxicity. We used the mAb to inhibit hNPC derived exosomes. In-vivo, the mAb limited the growth of hNPC tumors in humanized SCID mice. Second part: CD4+ T cell response is essential in managing NPC. The use of a CD4+ T cell response inducing peptide cocktail vaccination strategy was tested here. 6 HLA II promiscuous peptides derived from the 3 EBV latency II antigens were generated. These peptides induced IFNγ secretion by PBMCs. Generated peptide-specific CD4+ T cell lines showed highly cytotoxicity against NPC cell lines and resistance to hNPC exosomes. Invivo, the cocktail restrained tumor growth. Exvivo, it reactivated NPC patients’ memory T cells
La, Rochère Philippe de. "La souris humanisée : modèle d'étude de l'immunothérapie anti-cancer A comprehensive analysis of humanized mouse models for the study of cancer immunotherapies Inhibition of PI3K increases immune infiltrate in muscle invasive bladder cancer." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCB068.
Повний текст джерелаImmunotherapy is revolutionizing cancer treatment by shifting the treatment strategy from targeting the tumor to targeting the immune system. The blockade of immune checkpoints with anti-CTLA-4, anti-PD1 and anti-PD-L1 antibodies shows impressive clinical results. However, the response rate remains low. It is therefore essential to better understand the mechanisms of action of these therapies, to identify biomarkers of response and toxicity, and to evaluate therapeutic combinations. Such mechanistic and preclinical studies require the optimization of adapted murine models. For these purposes, my PhD work has focused on the development of humanized mouse models, in which immunodeficient mice are grafted with human tumor (cell lines or patient derived xenografts) and immune cells to study different immunotherapy approaches. In humanized mouse models, the human immune cell compartment can be reconstituted from either hematopoietic stem cells (HSC) from umbilical cord blood or with mononuclear cells from human blood (PBMC). We have observed that the injection of HSCs generates several subpopulations of immune cells (myeloid cells, T and B lymphocytes, NK cells), detectable from 4 weeks; while the injection of PBMCs mainly generates T lymphocytes, detectable from 1 week. In the latter model, lymphocyte reconstitution is associated with an anti-tumor effect, but is also accompanied by the development of graft-versus-host disease. Both models have advantages and disadvantages for the evaluation of cancer immunotherapies, which are discussed in my thesis. Using these models, we evaluated the therapeutic effect of a clinically used anti-PD1 antibody on tumor cell lines or on patient derived xenografts of different types of tumors. We observed a heterogeneity in the response to treatment, reflecting the clinical observation of responder and non-responder patients. Finally, in order to evaluate the interest of humanized mice for the study of therapeutic combinations, we tested an anti-PD1 therapy associated with a targeted therapy in bladder cancer. Our results, identifying the strengths and limitations of humanized mice, demonstrate the relevance of these new models for the evaluation of immuno-oncology therapies and open perspectives in the study of therapeutic combinations
Reinhart, Verena [Verfasser], Ernst J. [Akademischer Betreuer] Rummeny, and Vasilis [Akademischer Betreuer] Ntziachristos. "Monitoring of New Immunotherapies for Prostate Cancer with Optical Imaging / Verena Reinhart. Gutachter: Vasilis Ntziachristos ; Ernst J. Rummeny. Betreuer: Ernst J. Rummeny." München : Universitätsbibliothek der TU München, 2013. http://d-nb.info/1047883384/34.
Повний текст джерелаCoulon, Le Moignic Aline. "Développement d'une stratégie de vaccination thérapeutique antitumorale basée sur l'utilisation de lipopolyplexes à ARN ciblant les cellules dendritiques." Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066048/document.
Повний текст джерелаElimination of cancer cells requires an efficient cytotoxic immune response. In order to obtain such a response, antigens need to be uptaken by dendritic cells (DCs) and correctly presented to effector cells. We developed a strategy based on RNA lipopolyplexes (LPRs): antigenic mRNA is associated with a histidine-polylysine polyplexe and incorporated in a trimannosylated liposome to better target dendritic cells (DCs) in vivo, as DCs express several C-Type lectin receptors that preferentially bind to mannose. Here, we report that trimannosylated LPRs are efficient to target both human and murine DCs. Interestingly, in vivo experiments reveal that trimannosylated LPRs not only target DCs but also induce their recruitment and activation in draining lymph nodes. Furthermore, when combined with mRNA encoding E7 oncoprotein from HPV16, trimannnosylated LPRs trigger specific T-cell response against E7. Finally, when used as therapeutic vaccines in three different tumors models, LPRs promote curative therapeutic responses in E7-expressing TC1 tumor, in OVA-expressing EG7 lymphoma and in MART-1-expressing B16 melanoma, when combined with E7, OVA or MART-1 mRNA, respectively. Altogether, these results comfort us to considerate the use of this strategy for anti-cancer vaccine therapies
Marabelle, Aurélien. "Targeting Tumor Specific Regulatory T-cells for Cancer Therapy." Thesis, Lyon, École normale supérieure, 2013. http://www.theses.fr/2013ENSL0832.
Повний текст джерелаActivation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, regulatory T-cells (Tregs) eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti–CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response
Mall, Sabine [Verfasser], Angela [Akademischer Betreuer] [Gutachter] Krackhardt, and Iris [Gutachter] Antes. "In vivo monitoring of cancer specific TCR-engineered human T cells by Immuno-PET to analyze pharmacokinetics of T-cell based immunotherapies / Sabine Mall ; Gutachter: Angela Krackhardt, Iris Antes ; Betreuer: Angela Krackhardt." München : Universitätsbibliothek der TU München, 2016. http://d-nb.info/1121206778/34.
Повний текст джерелаSwanson, Anna May. "Novel immunotherapies for EBV-associated cancers." Thesis, University of Edinburgh, 2008. http://hdl.handle.net/1842/2683.
Повний текст джерелаКниги з теми "Cancer immunotherapies"
Hays, Priya, ed. Cancer Immunotherapies. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7.
Повний текст джерелаAscierto, Paolo A., David F. Stroncek, and Ena Wang, eds. Developments in T Cell Based Cancer Immunotherapies. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-21167-1.
Повний текст джерелаMartin, Gore, and Riches Pamela, eds. Immunotherapy in cancer. Chichester: Wiley, 1996.
Знайти повний текст джерела1918-, Yamamura Yūichi, and Azuma Ichiro, eds. Molecular and cellular networks for cancer therapy: From the International Symposium on Molecular and Cellular Networks for Cancer Therapy, May 20, 1988, Osaka, Japan. Amsterdam: Excerpta Medica, 1989.
Знайти повний текст джерелаT, Lotze Michael, Finn Olivera J, and Cetus Corporation, eds. Cellular immunity and the immunotherapy of cancer: Proceedings of a Cetus, Immunex, and Triton Biosciences-UCLA Symposia Colloquium held at Park City, Utah, January 27-February 3, 1990. New York: Wiley-Liss, 1990.
Знайти повний текст джерелаRamakrishnan, S. Cytotoxic conjugates. Austin: R.G. Landes Co., 1993.
Знайти повний текст джерелаC, Srivastava Suresh, and North Atlantic Treaty Organization. Scientific Affairs Division., eds. Radiolabeled monoclonal antibodies for imaging and therapy. New York: Plenum Press, 1988.
Знайти повний текст джерелаFantini, Massimo, and Roberto Bei, eds. Engineered Targeted Cancer Immunotherapies. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88976-669-7.
Повний текст джерелаAscierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana Press, 2015.
Знайти повний текст джерелаAscierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2015.
Знайти повний текст джерелаЧастини книг з теми "Cancer immunotherapies"
Aroldi, Francesca, Reem Saleh, Insiya Jafferji, Carmelia Barreto, Chantal Saberian, and Mark R. Middleton. "Lag3: From Bench to Bedside." In Cancer Immunotherapies, 185–99. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_6.
Повний текст джерелаMolvi, Zaki, and Richard J. O’Reilly. "Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer." In Cancer Immunotherapies, 131–59. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_4.
Повний текст джерелаBrown, Michael. "Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity." In Cancer Immunotherapies, 91–129. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_3.
Повний текст джерелаNavani, Vishal, Moira C. Graves, Hiren Mandaliya, Martin Hong, Andre van der Westhuizen, Jennifer Martin, and Nikola A. Bowden. "Melanoma: An immunotherapy journey from bench to bedside." In Cancer Immunotherapies, 49–89. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_2.
Повний текст джерелаLu, Kevin, Kun-Yuan Chiu, and Chen-Li Cheng. "Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution." In Cancer Immunotherapies, 201–23. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_7.
Повний текст джерелаHays, Priya. "Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies." In Cancer Immunotherapies, 287–315. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_11.
Повний текст джерелаCao, Handi, and Ryohichi Sugimura. "Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells." In Cancer Immunotherapies, 255–74. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_9.
Повний текст джерелаPerna, Fabiana, Manuel R. Espinoza-Gutarra, Giuseppe Bombaci, Sherif S. Farag, and Jennifer E. Schwartz. "Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia." In Cancer Immunotherapies, 225–54. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_8.
Повний текст джерелаVerma, Amitesh, and Sarwish Rafiq. "Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma." In Cancer Immunotherapies, 161–84. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_5.
Повний текст джерелаDeLucia, Diana C., and John K. Lee. "Development of Cancer Immunotherapies." In Cancer Immunotherapies, 1–48. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96376-7_1.
Повний текст джерелаТези доповідей конференцій з теми "Cancer immunotherapies"
Zhou, Hanbei. "Compare among Three Immunotherapies Against Cancer." In BIBE2020: The Fourth International Conference on Biological Information and Biomedical Engineering. New York, NY, USA: ACM, 2020. http://dx.doi.org/10.1145/3403782.3403786.
Повний текст джерелаLeiva Suero, Lizette Elena, Luis Fabián Salazar Garcés, Lizette Elena Leiva Suero, and Graciela de las Mercedes Quishpe Jara. "Development of immunotherapies in breast cancer." In 1er Congreso Universal de las Ciencias y la Investigación Medwave 2022;. Medwave Estudios Limitada, 2022. http://dx.doi.org/10.5867/medwave.2022.s2.uta043.
Повний текст джерелаYang, Xinlan. "Immunotherapies For Cancer, a Promising Cure?" In ISAIMS 2020: 2020 International Symposium on Artificial Intelligence in Medical Sciences. New York, NY, USA: ACM, 2020. http://dx.doi.org/10.1145/3429889.3429942.
Повний текст джерелаPeng, Songming, Jesse Zaretsky, Michael Bethune, Alice Hsu, John E. Heath, Won Jun Noh, Shannon Esswein, Antoni Ribas, David Baltimore, and James R. Heath. "Abstract IA17: Technologies for personalizing cancer immunotherapies." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; October 20-23, 2016; Boston, MA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/2326-6074.tumimm16-ia17.
Повний текст джерелаHeath, James R., Songming Peng, Alice Hsu, Shannon Esswein, John Heath, Won Jun Noh, Jesse Zaretsky, and Toni Ribas. "Abstract IA30: Technologies for personalizing cancer immunotherapies." In Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-ia30.
Повний текст джерелаRuan, Shasha, Ming Lin, Yongshun Chen, Elaine Hurt, Alfred E. Chang, Max S. Wicha та Qiao Li. "Abstract 375: Integrin β4-targeted cancer immunotherapies". У Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-375.
Повний текст джерелаRuan, Shasha, Ming Lin, Yongshun Chen, Elaine Hurt, Alfred E. Chang, Max S. Wicha та Qiao Li. "Abstract 375: Integrin β4-targeted cancer immunotherapies". У Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-375.
Повний текст джерелаCascante-Estepa, N., S. Mayrhofer, and H. Enzmann. "P04.03 Cancer immunotherapies, companion diagnostics and precision medicine." In iTOC9 – 9th Immunotherapy of Cancer Conference, September 22–24, 2022 – Munich, Germany. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-itoc9.39.
Повний текст джерелаSmyth, Mark J. "Abstract SY07-01: New targets in combination cancer immunotherapies." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-sy07-01.
Повний текст джерелаBlank, Christian. "Abstract PL02-03: Combination with/of immunotherapies." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-pl02-03.
Повний текст джерелаЗвіти організацій з теми "Cancer immunotherapies"
Cooper, Laurence. T-Cell Immunotherapies for Treating Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2011. http://dx.doi.org/10.21236/ada554845.
Повний текст джерелаKrishnamurthy, Janani. Immunotherapies for Targeting Ancient Retrovirus during Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, March 2014. http://dx.doi.org/10.21236/ada599067.
Повний текст джерелаLalani, Aly-Khan, and Bradley A. McGregor. The evolution of metastatic kidney cancer treatment: from interferons to the novel immunotherapies. BJUI Knowledge, November 2021. http://dx.doi.org/10.18591/bjuik.0744.
Повний текст джерелаRäber, Miro E., Dilara Sahin, Ufuk Karakus, and Onur Boyman. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0086.
Повний текст джерелаThe evolution of metastatic kidney cancer treatment: from interferons to the novel immunotherapies. BJUI Knowledge, October 2017. http://dx.doi.org/10.18591/bjuik.0107.
Повний текст джерела